Alpha 2.0
Login Register
» Articles » PMID: 33093123

Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: a Nationwide Cohort Study in South Korea

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2020 Oct 23
PMID 33093123
Citations 8
Authors
Yong-Soo Kwon
Doosoo Jeon
Hyungseok Kang
Jae-Joon Yim
Tae Sun Shim
Affiliations
Soon will be listed here.
Citing Articles

Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.

Putra O, Yulistiani Y, Soedarsono S, Subay S Perspect Clin Res. 2024; 15(2):89-93.

PMID: 38765544 PMC: 11101004. DOI: 10.4103/picr.picr_1_23.

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India.

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A, Galindo M J Clin Tuberc Other Mycobact Dis. 2024; 35:100433.

PMID: 38617837 PMC: 11015490. DOI: 10.1016/j.jctube.2024.100433.

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis.

Rehman O, Fatima E, Ali A, Akram U, Nashwan A, Yunus F J Clin Tuberc Other Mycobact Dis. 2023; 34:100405.

PMID: 38152568 PMC: 10750101. DOI: 10.1016/j.jctube.2023.100405.

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens.

Park H, Kwon J, Kim H, Kwon S, Nam J, Min S J Korean Med Sci. 2023; 38(21):e167.

PMID: 37270920 PMC: 10226853. DOI: 10.3346/jkms.2023.38.e167.

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.

Rodriguez C, Lodi S, Horsburgh C, Mitnick C, Bastard M, Huerga H PLOS Glob Public Health. 2023; 3(4):e0000818.

PMID: 37115740 PMC: 10146539. DOI: 10.1371/journal.pgph.0000818.